Skip to main content

Table 6 Cellular biomarkers and oxidative damage and their association to HSIL and cervical cancer development

From: TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions

  LSILa HSIL CC HSILa CC
OR OR CI p OR CI p OR OR CI p
TOP2A/MCM2 1.0 44.9 16.6–121.4 < 0.001 167.4 43.1–∞ < 0.001 1.0 2.6 0.6–∞ 0.183
p16INK4a 1.0 16.2 6.7–38.9 < 0.001 51.3 14.4–∞ < 0.001 1.0 1.9 0.5–∞ 0.312
Cyclin E 1.0 13.1 5.8–29.9 < 0.001 78.5 21.7–∞ < 0.001 1.0 3.9 0.9–∞ 0.060
Ki-67 1.0 17.7 7.5–41.4 < 0.001 89.0 24.1–∞ < 0.001 1.0 2.4 0.7–∞ 0.146
Telomerase 1.0 6.1 2.5–14.6 < 0.001 15.6 4.5–∞ < 0.001 1.0 1.4 0.4–∞ 0.562
RI-5 1.0 72.7 21.8–242.2 < 0.001 261 56.5–∞ < 0.001 1.0 2.8 0.7–∞ 0.152
RI-4 1.0 55.2 18.1–168.3 < 0.001 203.3 47.3–∞ < 0.001 1.0 3.0 0.8–∞ 0.110
RI-3 1.0 79.1 23.7–264.4 < 0.001 246.1 55.8–∞ < 0.001 1.0 2.8 0.7–∞ 0.140
RI-2 1.0 61.4 20.0–188.8 < 0.001 200.8 44.1–∞ < 0.001 1.0 2.2 0.6–∞ 0.224
ROS 1.0 0.7 0.5–1.0 0.055 0.3 0.2–0.5 0.30 1.0 0.4 0.2–0.7 0.003
8-OHdG 1.0 0.8 0.5–1.2 0.321 1.2 0.7–1.9 0.487 1.0 1.2 0.7–2.1 0.415
  1. LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E, and RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) areference category